InsiderClue
Stocks · Health care · Hospital & Medical Service Plans

CLOVER HEALTH INVESTMENTS, CORP.

CLOV Clue Score51
United States Fiscal year ends December CIK 0001801170 Results filed 4 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

71
Insider
Date
Role
Action
Shares
Price
Amount
Karen Soares
20 Oct 2026
Chief Legal Officer
Sold on a plan
19,275
$4.66
$89.82K
Jamie L. Reynoso
19 Oct 2026
CEO, Medicare Advantage
Sold on a plan
4,066
$4.41
$17.93K
Jamie L. Reynoso
15 Oct 2026
CEO, Medicare Advantage
Sold on a plan
18,273
$4.68
$85.52K
Conrad Wai
15 Oct 2026
CEO, Counterpart Health
Sold on a plan
23,627
$4.68
$110.57K
Joseph Clay Thornton
15 Oct 2026
Interim CFO
Sold on a plan
4,591
$4.68
$21.49K
Karen Soares
15 Oct 2026
Chief Legal Officer
Sold on a plan
14,673
$4.68
$68.67K
Andrew Toy
15 Oct 2026
Chief Executive Officer
Sold on a plan
62,176
$4.68
$290.98K
Jamie L. Reynoso
7 Oct 2026
CEO, Medicare Advantage
Sold on a plan
2,006
$4.63
$9.29K
Jamie L. Reynoso
5 Oct 2026
CEO, Medicare Advantage
Sold on a plan
8,750
$4.42
$38.68K
Andrew Toy
1 Oct 2026
Chief Executive Officer
Sold on a plan
318,806
$4.19
$1.34M
Jamie L. Reynoso
17 Sep 2026
CEO, Medicare Advantage
Sold on a plan
1,921
$4.56
$8.76K
Joseph Frank Oldakowski
16 Sep 2026
VP of Finance and Controller
Sold on a plan
3,170
$4.64
$14.71K
Conrad Wai
15 Sep 2026
CEO, Counterpart Health
Sold on a plan indirect
300,000
$4.72
$1.42M
Jamie L. Reynoso
15 Sep 2026
CEO, Medicare Advantage
Sold on a plan
9,273
$4.78
$44.32K
Karen Soares
15 Sep 2026
Chief Legal Officer
Sold on a plan
6,846
$4.78
$32.72K
Joseph Frank Oldakowski
14 Sep 2026
VP of Finance and Controller
Sell
20,000
$5.16
$103.20K
Joseph Clay Thornton
17 Aug 2026
Interim CFO
Sold on a plan
17,775
$4.39
$78.03K
Andrew Toy
10 Aug 2026
Chief Executive Officer
Sold on a plan
87,798
$4.65
$408.26K
Karen Soares
20 Jul 2026
Chief Legal Officer
Sold on a plan
51,700
$4.51
$233.17K
Jamie L. Reynoso
17 Jul 2026
CEO, Medicare Advantage
Sold on a plan
4,839
$4.53
$21.92K
Joseph Clay Thornton
15 Jul 2026
Interim CFO
Sold on a plan
4,630
$4.67
$21.62K
Karen Soares
15 Jul 2026
Chief Legal Officer
Sold on a plan
10,519
$4.67
$49.12K
Jamie L. Reynoso
15 Jul 2026
CEO, Medicare Advantage
Sold on a plan
13,119
$4.67
$61.27K
Conrad Wai
15 Jul 2026
CEO, Counterpart Health
Sold on a plan
24,215
$4.67
$113.08K
Andrew Toy
15 Jul 2026
Chief Executive Officer
Sold on a plan
62,711
$4.67
$292.86K
Jamie L. Reynoso
8 Jul 2026
CEO, Medicare Advantage
Sold on a plan
2,384
$4.68
$11.16K
Jamie L. Reynoso
6 Jul 2026
CEO, Medicare Advantage
Sold on a plan
6,229
$5.26
$32.76K
Andrew Toy
1 Jul 2026
Chief Executive Officer
Sold on a plan
313,476
$5.32
$1.67M
Jamie L. Reynoso
17 Jun 2026
CEO, Medicare Advantage
Sold on a plan
2,360
$4.78
$11.28K
Joseph Frank Oldakowski
16 Jun 2026
VP of Finance and Controller
Sold on a plan
12,102
$4.86
$58.82K
Jamie L. Reynoso
15 Jun 2026
CEO, Medicare Advantage
Sold on a plan
6,350
$4.61
$29.27K
Karen Soares
15 Jun 2026
Chief Legal Officer
Sold on a plan
4,681
$4.61
$21.58K
Jamie L. Reynoso
11 Jun 2026
CEO, Medicare Advantage
Sold on a plan
7,289
$4.91
$35.79K
Conrad Wai
28 May 2026
CEO, Counterpart Health
Sold on a plan indirect
220,426
$3.99
$879.50K
Carladenise Armbrister Edwards
18 May 2026
Director
Sell
67,160
$3.42
$229.69K
Brady Patrick Priest
13 May 2026
CEO of Clover Care Services
Sell
98,039
$3.52
$345.10K
Jamie L. Reynoso
18 Mar 2026
CEO, Medicare Advantage
Sold on a plan
5,833
$1.91
$11.14K
Brady Patrick Priest
4 Mar 2026
CEO of Home Care
Sell
175,000
$2.17
$379.75K
Jamie L. Reynoso
20 Jan 2026
CEO, Medicare Advantage
Sold on a plan
4,597
$2.58
$11.86K
Jamie L. Reynoso
7 Jan 2026
CEO, Medicare Advantage
Sold on a plan
2,102
$2.53
$5.32K
Jamie L. Reynoso
18 Dec 2025
CEO, Medicare Advantage
Sold on a plan
4,913
$2.61
$12.82K
Jamie L. Reynoso
4 Nov 2025
CEO, Medicare Advantage
Sold on a plan
30,385
$3.58
$108.78K
Jamie L. Reynoso
17 Oct 2025
CEO, Medicare Advantage
Sold on a plan
16,514
$2.69
$44.42K
Jamie L. Reynoso
7 Oct 2025
CEO, Medicare Advantage
Sold on a plan
2,012
$2.65
$5.33K
Jamie L. Reynoso
17 Sep 2025
CEO, Medicare Advantage
Sold on a plan
4,914
$3.09
$15.18K
Anna U Loengard
13 Aug 2025
Director
Buy indirect
14,500
$2.59
$37.56K
Anna U Loengard
13 Aug 2025
Director
Buy indirect
12,000
$2.60
$31.20K
Vivek Garipalli
8 Aug 2025
Director
Buy
31,980
$2.17
$69.40K
Vivek Garipalli
7 Aug 2025
Director
Buy
415,000
$2.24
$929.60K
Jamie L. Reynoso
4 Aug 2025
CEO, Medicare Advantage
Sold on a plan
6,823
$2.89
$19.72K
Conrad Wai
23 Jul 2025
CEO, Counterpart Health
Sold on a plan indirect
91,197
$3.32
$302.77K
Conrad Wai
22 Jul 2025
CEO, Counterpart Health
Sold on a plan indirect
118,600
$3.29
$390.19K
Jamie L. Reynoso
7 Jul 2025
CEO, Medicare Advantage
Sold on a plan
2,012
$2.85
$5.73K
Jamie L. Reynoso
3 Jul 2025
CEO, Medicare Advantage
Sold on a plan
19,789
$2.58
$51.06K
Jamie L. Reynoso
17 Jun 2025
CEO, Medicare Advantage
Sold on a plan
20,450
$2.86
$58.49K
Carladenise Armbrister Edwards
7 Mar 2025
Director
Sell
200,000
$3.61
$722.00K
Karen Soares
6 Mar 2025
General Counsel & Secretary
Sell
52,500
$3.80
$199.50K
Brady Patrick Priest
6 Mar 2025
CEO of Home Care
Sell
75,000
$3.68
$276.00K
Vivek Garipalli
9 Aug 2024
Director
Buy
531,700
$1.88
$999.60K
Vivek Garipalli
17 Jun 2024
Director
Buy
877,567
$1.14
$1.00M
Anna U Loengard
17 May 2024
Director
Buy indirect
10,000
$0.93
$9.30K
Anna U Loengard
16 May 2024
Director
Buy indirect
1,485
$0.94
$1.40K
Anna U Loengard
16 May 2024
Director
Buy indirect
15,600
$0.96
$14.98K
Anna U Loengard
14 Mar 2024
Director
Buy indirect
13,625
$0.73
$9.95K
Anna U Loengard
14 Mar 2024
Director
Buy
137,000
$0.73
$100.01K
Anna U Loengard
6 Sep 2023
Director
Buy indirect
500
$1.30
$650.00
Anna U Loengard
6 Sep 2023
Director
Buy indirect
500
$1.30
$650.00
Anna U Loengard
6 Sep 2023
Director
Buy indirect
10,000
$1.30
$13.00K
Lee Shapiro
11 Mar 2022
Director
Buy
80,000
$3.10
$248.07K
Chelsea Clinton
3 Mar 2022
Director
Buy
100,000
$2.53
$252.53K
Chamath Palihapitiya
22 Nov 2021
10% owner
Buy indirect
1,739,130
$5.75
$10.00M

What was left out

Form 4 filings counted 305
Amendments (4/A) skipped 10
Filings about a different issuer 0
Unreadable filings 0
Joint filings 5
Sales on a Rule 10b5-1 plan 47
Sales straight out of an exercise 0
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 152,934,025
History held since 11 Jan 2021